News

Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative…

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a…

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data…

TUCSON, Ariz., CAMBRIDGE, Mass., and ROSTOCK, Germany and BERLIN, June 20, 2024 – Critical Path Institute (C-Path), a leader in forming collaborations…

CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,…

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential…

Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research; Companies amend existing drug…

Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 2, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the…